Webinars
Available On Demand
Patient finding is more than a buzzword. Ready to challenge the status quo?
With more data, advancements in AIML and greater access to insights, it is not surprising that patient finding is evolving. Many pharma organizations have deep-rooted ideas about what patient finding requires, but they often miss the opportunity to put the patient at the center. Join Trinity Life Sciences’ experts as we debunk common misconceptions and discuss the actionable potential of patient finding throughout the drug development lifecycle. We…
Watch Now
White Papers
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023).
This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior).
The needle is moving.
Complete the form below to access the full white paper
By submitting…
Read Now
White Papers
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Key Takeaways from the 2023 NRDL Update
Continued importance of the NRDL
Accelerated access for innovative drugs
Evolving NRDL policy and payer landscape
Complete the form below to access the full white paper
By submitting this form, creating…
Read Now
Briefs
Improving partnerships is a crucial aspect of successful organizations. However, many companies face challenges in aligning their Commercial Operations and Information Technology teams. These conflicts often lead to inefficiencies in processes, resources and functionality, which ultimately impact the overall capabilities of the organization. To address these challenges, companies have implemented various strategies to enhance collaboration and alignment. Our observation suggests that the key to resolving these issues lies in fostering strong relationships between the teams.
During our conversations with industry…
Read Now
Webinars
Available On Demand
In your company, is it Sales, Marketing, Analytics, Operations, Medical…?
If you are struggling to answer this question, you are not alone. With the rising adoption of digital and virtual approaches to customer engagement, companies are facing more complexity in commercialization. Organizations that lack clarity find that achieving the desired impact from customer engagement strategies remains elusive—despite significant investment and transformation.
Join Trinity’s Customer Engagement experts in a lively panel discussion hosted by Nancy Phelan, Senior Vice President. We will…
Watch Now
Blog
Published October 1, 2024
The customer is changing
The landscape around life sciences is more competitive than ever, with a shorter runway to success and market dynamics (payer, competition, etc.) that are indisputably changing the role and level of influence at a customer level. These changes are happening at a hyper-local level, not just at a homogenous national level. And it is this shift in control and influence locally that causes complexity for pharma to identify, prioritize, reach and engage key customers. Personalized, customer-centric…
Read Now
Blog
Published September 25, 2024
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).
PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the disease progresses, it can lead to severe complications that may become life-threatening. PNH is listed in the first edition of China’s rare disease catalog, with…
Read Now
White Papers
Demonstrating the value of Field Medical Affairs has, to date, been a challenge due to its qualitative and non-promotional nature. Traditional, activity-based metrics have missed the mark on translating Field Medical Affairs activities to tangible milestones, such as changes in HCP perception, HCP advocacy or closing critical care gaps that impact overall patient outcomes.
When developing Key Medical Objectives (KMOs) and impact measurement models for Field Medical Affairs, several factors must be considered: the organization’s size, structure, specific roles, therapeutic…
Read Now
Blog
Published September 17, 2024
What does orchestration mean for a brand?
True orchestration considers a customer’s preferences before communicating with them. Learnings from past interactions and outcomes are used to identify the most relevant action to lead to a rewarding experience for both the customer and the brand. Orchestration can be defined as all channels learning from each other to create better “surround sound” for the customer.
Orchestration for a brand means that you have a thoughtfully-built decision engine that can process historical customer…
Read Now
Blog
Published September 12, 2024
The short answer is yes, by powering process automation with GenAI. It’s an approach that hasn’t received as much attention as other GenAI use cases within life sciences, but the results can be very powerful.
To illustrate its power, we’ll examine a case study on identifying debarred healthcare professionals (HCPs).
Why is it important to identify debarred HCPs?
Pharmaceutical companies are mandated to cease all forms of engagement with debarred healthcare professionals (HCPs) in the U.S.
Compliance entails identifying and…
Read Now
